Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc.    RARE

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
112.82(c) 114.37(c) 114.69(c) 118.88(c) 123.78 Last
305 356 266 546 192 685 398 173 46 389 Volume
-1.08% +1.37% +0.28% +3.65% +4.12% Change
More quotes
Financials (USD)
Sales 2020 247 M - -
Net income 2020 -240 M - -
Net cash position 2020 663 M - -
P/E ratio 2020 -30,7x
Yield 2020 -
Sales 2021 330 M - -
Net income 2021 -277 M - -
Net cash position 2021 445 M - -
P/E ratio 2021 -28,0x
Yield 2021 -
Capitalization 7 865 M 7 865 M -
EV / Sales 2020 29,1x
EV / Sales 2021 22,5x
Nbr of Employees 740
Free-Float 94,6%
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.... 
More about the company
Notations Surperformance© of Ultragenyx Pharmaceutical Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ULTRAGENYX PHARMACEUTICAL INC.
09:55aULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Healthcare Conferences
AQ
11/24ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Healthcare Conferences
AQ
11/24Ultragenyx to Present at Upcoming Healthcare Conferences
GL
11/20ULTRAGENYX PHARMACEUTICAL : Corporate Presentation
PU
11/09ULTRAGENYX PHARMACEUTICAL : Corporate Presentation
PU
11/09ULTRAGENYX PHARMACEUTICAL : Announces Plans to Build Large-scale Gene Therapy Ma..
AQ
11/09Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Fa..
GL
11/05ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/05Ultragenyx to Present at Upcoming Investor Conferences
GL
11/04ULTRAGENYX PHARMACEUTICAL : Statement of changes in beneficial ownership of secu..
PU
11/02ULTRAGENYX PHARMACEUTICAL : Statement of changes in beneficial ownership of secu..
PU
11/02ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement, Fin..
AQ
11/02ULTRAGENYX PHARMACEUTICAL : Announces Closing of Public Offering of Common Stock..
AQ
11/02Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exer..
GL
10/30ULTRAGENYX PHARMACEUTICAL : Statement of changes in beneficial ownership of secu..
PU
More news
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.

- No features available -

More news
Stock Trading Strategies
ULTRAGENYX PHARMACEUTICAL INC. - 10/30
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 105,65 $
Last Close Price 118,88 $
Spread / Highest target 7,67%
Spread / Average Target -11,1%
Spread / Lowest Target -46,2%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Mardi C. Dier Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC.178.34%7 865
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.59.64%38 761
BIONTECH SE200.68%24 529